Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of miR-210 and combination biomarkers as useful agents in early screening non-small cell lung cancer

9 Dec 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circular RNAs in diseases
Share to Lung Cancer Treatments and Mutations
Share to MicroRNA in disease regulation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31830514
DOI: 10.1016/j.gene.2019.144225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of miR-210 and combination biomarkers as useful agents in early screening non-small cell lung cancerPMID 31830514Read ↗

Identification of Circulating miR-210 as a Promising Biomarker for Lung AdenocarcinomaSemantic proximity Read ↗

A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancerSemantic proximity Read ↗

MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray dataSemantic proximity Read ↗

Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma.Semantic proximity Read ↗

Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancerSemantic proximity Read ↗

The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy.Semantic proximity Read ↗

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerSemantic proximity Read ↗

miR-708-5p Enhances Erlotinib/paclitaxel Efficacy and Overcomes Chemoresistance in Lung Cancer CellsSemantic proximity Read ↗

MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to CisplatinSemantic proximity Read ↗

A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung AdenocarcinomaSemantic proximity Read ↗

Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patientsSemantic proximity Read ↗

Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.